The Lancet

Stories

Mitapivat trial meets anemia endpoint, misses pain crisis target in sickle cell disease

Publisher of the RISE UP phase 3 results

A global phase 3 trial published in The Lancet found that mitapivat, an oral pyruvate kinase activator, raised hemoglobin in 41% of sickle cell disease patients, versus 3% on placebo. The drug missed its other primary endpoint: annualized pain crises fell from 3.1 to 2.6 per year, a gap that did not reach statistical significance.

Updated 2 hours ago

Coached lifestyle programs improve dementia-risk cognition more than advice alone

New Capabilities

Published the LatAm-FINGERS and FINGER trial results

Older adults at risk for dementia improved their thinking 55% more over two years with a coached lifestyle program than with health advice alone. The result comes from LatAm-FINGERS, a 1,065-person trial across 11 Latin American countries, reported July 13 at the Alzheimer's Association International Conference in London and in The Lancet.

Updated Sep 8